Morgan Stanley raised the firm’s price target on Schrodinger (SDGR) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger initiated with a Neutral at UBS
- BofA shakes up ratings in Biopharma Services with seven changes
- Schrodinger upgraded to Buy from Neutral at BofA
- Cathie Wood’s ARK Investment buys 36.6K shares of Schrodinger today
- FDA guides on streamlined nonclinical monoclonal antibody safety studies